anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Depression is a serious illness that can interfere with everyday life. Researchers believe that it is one of the most common complications during and after pregnancy. Depression after pregnancy is called postpartum depression and may be caused by a rapid change in hormone levels during and immediately after pregnancy. Postpartum depression can occur anytime within the first year after childbirth and can negatively affect both mothers and their children. Mothers with postpartum depression may experience low energy, difficulty concentrating, irritability, and inability to meet their children's needs for love and affection. As a result, women with postpartum depression may feel guilty and lose confidence in themselves as parents. Research shows that children of mothers with postpartum depression may have delays in language development, difficulty with emotional bonding to others, behavioral problems, lower activity levels, sleep problems, and distress. This study will evaluate the effectiveness of a telephone-based depression screening and care management program in treating depression in postpartum women.

Participants in this single blind study will be randomly assigned to receive either enhanced treatment as usual or telephone-based care management for the first year postpartum. All participants will have a 90-minute in-home interview upon study entry to assess depressive symptoms, functional status, medical history, and post-pregnancy plans. Participants assigned to care management will receive two calls in the first month postpartum, followed by monthly calls for the remainder of the first postpartum year. During each 10- to 20-minute call, participants will be asked to provide information regarding current depressive symptoms, steps they have taken to seek depression-related care, and any barriers they have encountered in the process. In addition, a care manager will act as an advocate for the participants and assist in obtaining specialized services as necessary throughout the year. Participants assigned to receive enhanced treatment as usual will not receive monthly phone calls or tailored care management. All participants will receive follow-up calls at 3, 6, and 12 months postpartum to assess outcome measures; these calls will last about 30 minutes.
The Neural Prosthetic System 2 consists of three Neuroport Arrays, which are described in detail in the intervention description. Two of the three Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The third Neuroport Array is inserted into somatosensory cortex, specifically S1 which represents sensory feedback for the hand and fingers. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought augmented with sensory feedback via intracortical microstimulation. They will then use the end effector to perform various reach and grasp tasks.
PURPOSE:To form permanent waves parallel to the peripheral surface of a head, by fixing a hair bundle on a plate having a desired width and length, sticking the hair bundle to the plate with an adhesive, softening the hair bundle with an agent, forming waves along the plate surface, and fixing the formed waves. CONSTITUTION:Hair is bundled into a hair bundle 1 of a necessary width and length, and a plate 2 is placed under the hair bundle 1 to insert the circular arc edge 3 thereof in the root of the hair bundle 1. The hair bundle 1 is then nipped by pipes 4 and 4', and the root is fixed on the plate 2 by nipping rubber bands 5. The hair bundle 1 is then stuck to the plate 2 with an adhesive. The root of the hair bundle 1 is softened with the first solution by the cold permanent waving method and then nipped between fingers with the plate 2 and all. Waves are formed by a comb and the tips of the fingers from above the hair bundle 1, and free waves are formed by the sticking of the hair bundle 1. The hair bundle 1 is then treated with the second solution to fix the waves. The amount of the agent can be changed for the root and the tip parts, and the damage of the hair can be suppressed.
INTRODUCTION: Keloid is an abnormal proliferation of scar tissue that grows beyond the original margins of the injury. Even after complete resection, recurrences are common and pose a poorly understood challenge in dermatology. There is lack of large prospective clinical trials; thus, treatment recommendations are based on retrospective analyses and small cohort studies. Superficial radiotherapy is recommended in recurrent keloids; however, the successful treatment rates vary greatly. The aim of this study was to evaluate the keloid recurrence rate after post-excision soft X-ray radiotherapy and the associated factors.
METHODS: We reviewed retrospective data of all patients, treated with adjuvant post-excision soft X-ray radiotherapy with 12 Gy in 6 sessions at the tertiary referral center, Department of Dermatology, University Hospital Zurich, Switzerland, between 2005 and 2018. We analyzed individual keloids as separate cases. Successful treatment was defined as no sign of recurrence within 2 years.
RESULTS: Of the 200 identified patients, 90 met the inclusion criteria and were included in the final analysis. In 90 patients, 104 cases of treated keloids were analyzed. Keloids were mainly located on the trunk (49%) and were mostly caused by previous surgery (52.2%). 50% of the keloids did not relapse within 2 years after therapy. A significant factor leading to recurrence was the presence of previous therapy, with prior topical therapies, such as steroid injections or 5-fluorouracil, leading to most relapses. 69.2% of keloid cases who relapsed were pretreated. Soft X-ray radiotherapy was well tolerated, with posttreatment hyperpigmentation noted in 34% of patients, particularly in patients with non-Caucasian origin (61.3%).
CONCLUSION: Treatment of refractory keloids is difficult. Post-excision radiotherapy is an established adjuvant treatment option; nevertheless, recurrence rates are high, especially in pretreated keloids. Prospective studies determining the exact dosage and fraction of post-excisional radiotherapy are needed to determine the optimal radiation parameters.
In this study, participants will be recruited from several family practice, pulmonologist, and asthma specialist offices in southwest Virginia. These participants will undergo two visits. At the first visit, a lung assessment comprised of three components will be performed, then a 10 minute OMT session, then the lung assessment will be repeated. The lung assessment includes a patient symptom survey, a thoracic excursion measurement, and spirometry. The participants will then be divided into one of two groups. Group 1 will have no further instruction while group 2 will be taught some simple home OMT techniques and asked to do them at home. Both groups will return two weeks later for a follow up lung assessment. Results when then be studied to determine the effect of OMT on lung function in asthmatics as well as the effect of incorporating home OMT. In addition, physicians will be involved in learning about OMT and these techniques and they will be assessed for a change in attitude, awareness, and willingness to incorporate OMT when applicable.
FIELD: medicine. SUBSTANCE: method involves applying laser drug photophoresis with hordox, followed by continuous laser irradiation of pancreas destruction focus. Wavelength is 0.63 mcm, power is 1.5 mW, distance to destruction focus is 0.5 cm. Single exposure is carried out during the operation and 20 min daily during 4-5 days after the operation. The treatment is combined with concurrent session of intravascular laser irradiation of blood with laser radiation. Wavelength is 0.63 mcm, power is 2 mW transferred through monofiber polymer light guide of 0.5 mm diameter during 40 min. EFFECT: reduced drug consumption; enhanced effectiveness of treatment; accelerated treatment of patients in hospital. 1 tbl
FIELD: medicine. SUBSTANCE: method involves checking plantar reflex as a characteristic of patient health state. Only healthy persons have the plantar reflex normally expressed. Pathologic or low level plantar reflex being observed, some therapeutic remedies are to be prescribed and corrected when needed in the course of treatment. The prescribed remedies are only cancelled when stable normalization of the plantar reflex is achieved. EFFECT: enhanced effectiveness of treatment control.
PURPOSE:To obtain the titled ointment, containing thrombin as an active ingredient, capable of sticking to local parts of living bodies, exhibiting sustained local hemostatic effects, closely adhering particularly to mucosal tissues without readily decomposing and running off by intraoral saliva and giving biohazard action to the living bodies. CONSTITUTION:A thrombin ointment obtained by containing thrombin as an active ingredient. In use, a formulation is prepared by using a method for blending part of a base such as ointment base, e.g. fat, lanolin, etc., emulsifying agent, e.g. sorbitan ester of a fatty acid, etc., preservative, e.g. p-hydroxybenzoic acid ester, etc., with the active ingredient, thoroughly triturating the blend, adding the residual base to further triturate the blend and forming the whole homogeneous blend, etc. The amount of the blended active ingredient is preferably about 100-1,000 units based on 1g ointment. Furthermore, the thrombin is produced by activating prothrombin which is a coagulation factor precursor contained in blood plasma.
Pexidartinib capsules administered twice daily in the morning and evening. Each cycle of treatment is 28 days in duration. The cycle of treatment is continued until disease progression, unacceptable toxicity, or consent withdrawal.
Participants in this arm will receive an ultrasound-guided injection of 5% dextrose solution into the sacrotuberous ligament and the sensory innervation area of the perforating cutaneous nerve. The intervention aims to alleviate symptoms of chronic coccydynia by reducing nerve entrapment. Participants will continue their existing physical therapy/medical treatment regimen throughout the study.
PURPOSE: A composition of water-soluble transparent gel toilet water is provided to reduce the stickiness and to enhance the optical stability. CONSTITUTION: A water-soluble transparent gel toilet water composition contains 0.05-2 wt.% of carbomer 940 for a water-soluble polymer, 0.5-8 wt.% of methyl glucess-20 for a stickiness-prohibiting and moisturizing agent, and trisodium EDTA and benzophenone-5 for the optical stability. The amounts of the trisodium EDTA and the benophenone-5 each are 0.5-5 wt.% of the weight of the carbomer. In a method of preparing the toilet water composition, purified water, carbomer, methyl glucess-20, trisodium EDTA and benzophenone-5 are mixed with each other, and diffused. A mixture solution of ethanol, antiseptic and perfume is added to the diffused solution. Triethanol amine is added to the mixture, and the mixture is neutralized, and air-released.
Aim 1: Ascertain the safety of the system and device in patients undergoing cochlear implantation (CI). Mild therapeutic hypothermia will be delivered to the subjects during CI surgery via the ear canal.
Arm 1: Day 1: aprepitant 125 mg capsule; ondansetron 8 mg capsule prior to chemotherapy and 1 8mg capsule 12 hrs after first dose; dexamethasone 12 mg tablets + 2 dexamethasone Pbo tablets. Day 2: Aprepitant 80 mg capsule; Ondansetron 8 mg capsule every 12 hours Day 3: Aprepitant 80 mg capsule Ondansetron 8 mg capsule every 12 hours.
OBJECTIVE: To identify distinct sleep health phenotypes in adults, examine transitions in sleep health phenotypes over time, and subsequently relate these to the risk of chronic conditions.
METHODS: A national sample of adults from the Midlife in the United States study ( N = 3683) provided longitudinal data with two time points (T1: 2004-2006, T2: 2013-2017). Participants self-reported on sleep health (regularity, satisfaction, alertness, efficiency, duration) and the number and type of chronic conditions. Covariates included age, sex, race, education, education, partnered status, number of children, work status, smoking, alcohol, and physical activity.
RESULTS: Latent transition analysis identified four sleep health phenotypes across both time points: good sleepers, insomnia sleepers, weekend catch-up sleepers, and nappers. Between T1 and T2, the majority (77%) maintained their phenotype, with the nappers and insomnia sleepers being the most stable. In fully adjusted models with good sleepers at both time points as the reference, being an insomnia sleeper at either time point was related to having an increased number of total chronic conditions by 28%-81% at T2, adjusting for T1 conditions. Insomnia sleepers at both time points were at 72%-188% higher risk for cardiovascular disease, diabetes, depression, and frailty. Being a napper at any time point related to increased risks for diabetes, cancer, and frailty. Being a weekend catch-up sleeper was not associated with chronic conditions. Those with lower education and unemployed were more likely to be insomnia sleepers; older adults and retirees were more likely to be nappers.
CONCLUSION: Findings indicate a heightened risk of chronic conditions involved in suboptimal sleep health phenotypes, mainly insomnia sleepers.
The invention provides an anticancer composition for treating solid tumors. The anticancer composition comprises an anticancer effective constituent and a pharmacy-acceptable carrier. The anticancer effective constituent is one or more kinds of matrix metalloproteinase and is preferably one or any combination of MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13 and MMP-18. The invention further provides an application of the anticancer composition to preparing of medicine for treating solid cancers. The anticancer composition is suitable for injection or implantation in tumor lesions, injection or implantation on the peripheries of tumors and injection or implantation in tumor cavities generated after a cancer operation. The anticancer composition can be prepared into various medicine dosage forms and preferably prepared into injection.
Approximately 40 eyes will be randomized at 3 investigational centers in the United States. This study consists of a screening period of up to 14 days (Days -14 to -1), and a 36-month treatment period (Day 0 to Month 36). Subjects who provide consent will enter the screening period to determine eligibility. As part of the screening process, the examining investigator will evaluate the macular foveal avascular zone fluorescein images to determine subjects' eligibility. Eligible subjects will be randomized in a 1:1 ratio so that approximately 20 eyes will receive 0.3 mg ranibizumab monotherapy, and approximately 20 eyes will receive 0.3 mg ranibizumab combined with Ultra wide 200° field angiogram guided targeted pan retinal photocoagulation (PRP). Subjects must meet VA and retinal thickness eligibility requirements during the screening period. The subject can have both eyes in the study. If both eyes are eligible, one eye will be randomized, to cohort 1 while the other eye will be randomized to the cohort 2. A subject with both eyes in the trial will have each eye in a separate cohort.
Extubation criteria: pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg; pH ≥ 7.25; SpO2 ≥ 88% with FiO2 ≤ 0.50; mean airway pressure (MAP) \< 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude \< 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 \> 55mmHg; pH \< 7.25; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (\> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
BACKGROUND: Older adults are increasingly susceptible to prolonged illness, multiple chronic diseases, and disabilities, which can lead to the coexistence of multimorbidity and frailty. Multimorbidity may result in various noncommunicable disease (NCD) patterns or configurations that could be associated with frailty and death. Mortality risk may vary depending on the presence of specific chronic diseases configurations or frailty.
METHODS: The aim was to examine the impact of NCD configurations on mortality risk among older adults with distinct frailty phenotypes. The population was analyzed from the Costa Rican Longevity and Healthy Aging Study Cohort (CRELES). A total of 2,662 adults aged 60 or older were included and followed for 5 years. Exploratory factor analysis and various clustering techniques were utilized to identify NCD configurations. The frequency of NCD accumulation was also assessed for a multimorbidity definition. Frailty phenotypes were set according to Fried et al. criteria. Kaplan‒Meier survival analyses, mortality rates, and Cox proportional hazards models were estimated.
RESULTS: Four different types of patterns were identified: 'Neuro-psychiatric', 'Metabolic', 'Cardiovascular', and 'Mixt' configurations. These configurations showed a higher mortality risk than the mere accumulation of NCDs [Cardiovascular HR:1.65 (1.07-2.57); 'Mixt' HR:1.49 (1.00-2.22); ≥3 NCDs HR:1.31 (1.09-1.58)]. Frailty exhibited a high and constant mortality risk, irrespective of the presence of any NCD configuration or multimorbidity definition. However, HRs decreased and lost statistical significance when phenotypes were considered in the Cox models [frailty + 'Cardiovascular' HR:1.56 (1.00-2.42); frailty + 'Mixt':1.42 (0.95-2.11); and frailty + ≥ 3 NCDs HR:1.23 (1.02-1.49)].
CONCLUSIONS: Frailty accompanying multimorbidity emerges as a more crucial indicator of mortality risk than multimorbidity alone. Therefore, studying NCD configurations is worthwhile as they may offer improved risk profiles for mortality as alternatives to straightforward counts.
A method of making a homogeneous solid particulate blend of solid initial ingredients involves dissolving in an aqueous solvent a sugar that is sublimable to dryness, a lesser amount of a biological product, and, if the biological product is not sufficiently lubricative, a lubricant; spraying this solution into boiling dichlorodifluoromethane or other fluorocarbon refrigerant; and lyophilizing the resulting frozen droplets. The sugar is usually either mannitol, maltose, lactose, inositol or dextran, or combinations of these sugars. Other sugars in an amount less than the above sugars may also be added to the solution. Less than about 5 percent w/v of an electrolyte may beneficially be added to the solution, as well as other substances, such as acid, base, etc. Ultrasonic waves applied to the fluorocarbon refrigerant in the region where the solution is sprayed increases the freezing rate. Limiting the distribution of sizes of those particles to be tabletted increases the weight homogeneity of the resulting tablets.
PROBLEM TO BE SOLVED: To provide a method for hair nourishing and growing treatment so as to wet scalp at a desired part with a hair grower readily, simply and efficiently without selecting a place by applying the hair grower to scalp and then heat-treating the scalp by a specific hair heater. SOLUTION: After a hair grower is applied to scalp, which is heat-treated with a hair heater 1 including heating elements or thermal storage elements 3. Iron powder is used as the heating elements 3 of the heater 1. Preferably the structure of the heater 1 is one sticking fast to the hair and the hair grower contains ethanol. For example the heater 1 comprises a cap 20 obtained by bonding mutual curved peripheral end parts 10a of two semielliptic sheets 10 of approximately the same shape containing heating elements or thermal storage elements and fixing the sheets. The sheets 10 are bonded and fixed to water- resistant inner layer sheets 2 so as to position the inner layer sheets inside.
The present invention relates to: a method for preparing an extract of a ginger by-product including ginger leaves, ginger stems, ginger root, and a mixture thereof; a perm agent composition for hair perm waves and straight hair, having an odor removal effect by including the extract; and a method for preparing a perm agent using the composition, and more specifically, contains cysteine HCL, glutamic acid, and purified water, and has an acidity. According to the present invention, when preparing a perm agent having the same function, through an extract of a ginger by-product (ginger leaves, ginger stems, ginger root, and a mixture thereof), which is the basis of the invention, a function of making a perm or wave is implemented in the same way and a chemical odor during or after the procedure is significantly reduced. Provided is a method for preparing an application for a deodorizing agent capable of removing foul odor by including the extract. More specifically, the present invention contains ethanol, fragrance, purified water, or alcohol. Accordingly, when the application capable of removing foul odor is used during a perm procedure by using a spray method or a direct application method, foul odor during the perm procedure can be significantly reduced. In addition, the application can have the same effect when being applied to other places with foul odor. Residues left after obtaining a ginger by-product extract are used as firewood pellets and supplements thereof so as to reduce agricultural waste which may be accidentally generated. Residues left after obtaining the ginger by-product extract are used as livestock feed and supplements thereof so as to reduce agricultural waste which may be accidentally generated.
This invention provides a method of modifying a cellular response in a mammal. The method comprises administering to the mammal an effective amount of biodegradable nanoparticles, each of said nanoparticles comprising an active agent, a biodegradable polymer, and a bone targeting agent administering to a mammal an effective amount of a composition comprising a compound absorbed in a biodegradable nanoparticle which is attached to a bone targeting agent. The invention also provides a method for modifying a cellular response in a mammalian cell comprising contacting the mammalian cell with biodegradable nanoparticles. The invention further provides a method of delivering an exogenous substance to a mammal. The method comprises administering to the mammal a composition comprising the exogenous substance absorbed into a biodegradable nanoparticle, wherein the biodegradable nanoparticle is covalently attached to a bone targeting agent. The invention also provides a composition and a process for preparing the composition comprising a biologically active or therapeutic agent of compound, a biodegradable nanoparticle, and a bone targeting agent.